Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triplex
- Development stage
- Phase 2
- Lead developer
- Helocyte
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
Triplex is a universal recombinant Modified Vaccinia Ankara (MVA) viral vector vaccine designed to induce a robust and durable T-cell response against cytomegalovirus (CMV). It is engineered to express three highly immunogenic CMV antigens: phosphoprotein 65 (pp65) and immediate-early proteins 1 and 2 (IE1 and IE2). Originally developed by City of Hope and exclusively licensed to Helocyte (a subsidiary of Fortress Biotech), Triplex is primarily being evaluated for the prevention and control of CMV reactivation and disease in immunocompromised populations. This includes patients undergoing allogeneic hematopoietic cell transplantation (HCT) and solid organ transplants, such as liver transplantation, as well as individuals co-infected with HIV. The vaccine aims to reduce CMV-related morbidity and mortality by enhancing CMV-specific T-cell immunity.
- Brand names
- Triplex
- Other names
- CMV-MVA TriplexTriplex CMV vaccine
02
Targets
HCMV Pentamer (HCMV pentameric glycoprotein complex)gB (Human cytomegalovirus glycoprotein B)pp65 (Cytomegalovirus phosphoprotein 65)IE1 (HCMV immediate-early protein 1)HCMV (Human cytomegalovirus)
Beyond the preview
Go deeper on Triplex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triplex.